Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-06-15

FDA Approved: CAMZYOS — Supplemental Application (Myokardia, Inc.)

View source ↗

Summary

FDA approved a supplemental application for CAMZYOS (mavacamten) submitted by Myokardia, Inc. The action represents an additional approval related to the drug's…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CAMZYOS (MAVACAMTEN)

Snippet

SUPPL AP for CAMZYOS (MAVACAMTEN)